Skip to main content

A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant



Unintended pregnancies (UIP) have a significant impact on health of women and the health budget of countries. Contraception is an effective way to prevent UIPs. The study objective was to collate evidence on clinical effectiveness of etonogestrel subdermal implant (ESI), continuation rate and side effect profile among eligible women of reproductive age group, as compared to levonorgestrel intrauterine system (LNG-IUS), copper intrauterine device (Cu-IUD) and depot medroxy progesterone acetate injections; other types of contraceptive implants were excluded as comparators.


The protocol of the systematic review was registered in Prospero (registration number: CRD42018116580). MEDLINE via PubMed, Cochrane library and web of science were the electronic databases searched. A search strategy was formulated and studies from 1998 to 2019 were included. Clinical trial registries and grey literature search was done. Critical assessment of included studies was done using appropriate tools. A qualitative synthesis of included studies was done and a meta-analysis was conducted in RevMan software for continuation rates of ESI as compared to other long acting reversible contraceptives (LARC) e.g. LNG IUS and Cu-IUD.


The search yielded 23,545 studies. After excluding 467 duplicates, 23,078 titles were screened and 51 studies were included for the review. Eight of the 15 studies reporting clinical effectiveness reported 100% effectiveness and overall pearl index ranged from 0 to 1.4. One-year continuation rates ranged from 57–97%; 44–95% at the end of second year and 25–78% by 3 years of use. Abnormal menstruation was the most commonly reported side effect. There was no significant difference in bone mineral density at 1 year follow-up. The meta-analyses showed that odds ratio (OR) of 1-year continuation rate was 1.55 (1.36, 1.76) for LNG-IUS vs. ESI and 1.34 (1.13, 1.58) for copper-IUD vs. ESI; showing that continuation rates at the end of one-year were higher in LNG-IUS and copper-IUD as compared to ESI.


ESI is clinically effective and safe contraceptive method to use, yet 1-year continuation rates are lower as compared to LNG-IUS and copper-IUD, mostly attributed to the disturbances in the menstruation.

Peer Review reports

Plain English summary

The choice of becoming pregnant and timing it right in the life course of women depends on multiple biological, social and psychological factors. With improving access to contraception, in an ideal scenario, every pregnancy should be wanted and planned. However unplanned pregnancies still occur and some of the reasons are limited choice, inadequate access to contraceptive methods and their side effects. Unintended pregnancies have a large impact not only on the physical health of women (unsafe abortions and maternal deaths), but also on their social and psychological make-up. The burden of unintended pregnancies is very high at about 87 million a year. Improving the basket of choice of contraceptives is known to reduce unintended pregnancies. Etonogestrel implant is one such contraceptive that has not been available through government supported family planning programs in some countries including India. This implant contains a synthetic hormone called ‘etonogestrel’ packaged inside a special plastic rod, the size of a small matchstick. It can be placed under the skin of the arm (subdermal) and left in place for three years to prevent pregnancy by slow release of the hormone. Our research aimed at compiling evidence on this contraceptive implant using a systematic search strategy to assess how well it works, how many women continue using it for the prescribed period of three years and what were the side-effects. We found that ESI worked very well, it prevented pregnancies to a great extent, but due to its side-effects especially abnormal menstrual bleeding, a range of 30–70% women did not use the method for the complete 3-year period.


Unintended pregnancies are a major concern in our world, due to the psychological and economic distress they cause. About 45% of all pregnancies were unwanted/unintended in the years 2010–2014 [1]. They have a large impact on health of women due to unsafe abortions and maternal deaths [2]. Contraception, if used appropriately, prevents unintended pregnancies [3] and their consequences. One of the relatively newer methods of contraception is the contraceptive implant. Studies show that the etonogestrel implant is effective, yet there is evidence that the side-effect profile of the implant results in high rates of discontinuation. This systematic review aimed to collate evidence on clinical effectiveness, continuation rates and side-effect profile of the etonogestrel subdermal contraceptive implant (ESI), as a part of a health technology assessment (HTA). ESI is a long acting reversible contraceptive method that contains 68 mg of Etonogestrel. It is flexible and measures four centimetres in length and two millimetres in breadth; it is inserted under the skin of the upper arm of a woman, by a trained health care provider. Once inserted sub dermally in the arm, it can be left in place for three years; removal needs a small surgical incision. Etonogestrel is an artificial active metabolite of the synthetic progestin called ‘Desogestrel’ [4]. Its contraceptive effect is mainly because it prevents the release of luteinizing hormone (LH) and hence prevents ovulation. It thickens the cervical mucus and this reduces the entry of spermatozoa. It also modifies the endometrium and inhibits implantation of the fertilized ovum [5]. The previous generation of this implant was called “Implanon”. However the improvised version Nexplanon/Implanon-NXT additionally contains barium, rendering it radio-opaque, and a differently designed insertion device. An addendum to a clinical guideline for long acting reversible contraceptive (LARC) by United Kingdom National Institute for Health and Care excellence (UK NICE) had a consensus that as Nexplanon/Implanon-NXT was bioequivalent to Implanon, the literature on Implanon was considered to update the guidelines on LARC implants [6]. ESI is indicated in women who are not pregnant and are of reproductive age (15–45 years) who wish to prevent pregnancy. According to the World Health Organization (WHO) medical eligibility criteria, it is contraindicated in women with history of deep vein thrombosis, severe liver disease and breast cancer [7]. The objectives of this systematic review were to estimate incidence of unintended pregnancy/contraceptive failure rate, continuation rate and side-effects of ESI as compared with levonorgestrel intrauterine system, copper intrauterine device, and depot medroxy progesterone acetate.


The protocol of this systematic review was registered and is available on Prospero (CRD42018116580, In this review we included studies that fit the inclusion criteria defined below and studies that were in English language. The population of interest for this review were women of reproductive age group 15–49 years who were eligible for contraception. The intervention of interest in this systematic review was etonogestrel sub dermal contraceptive implant (ESI). The comparators considered were copper Intra uterine devices (IUD), levonorgestrel IUS and contraceptive injectable (depot medroxy progesterone acetate i.e. DMPA). Studies with at least one of these as comparators or no comparator were included. The systematic review included studies published between January 1998 and December 2019 and grey literature. The study designs that were included were randomized control trials, non-randomized trials and observational studies. Observational studies included cross-sectional, case–control and cohort studies. The primary outcome that was assessed for effectiveness of the etonogestrel sub dermal contraceptive implant was unintended pregnancy rate/failure rate/pearl index while secondary outcomes included side effects/adverse events and continuation/discontinuation rates.

Operational definitions used in this review

Long acting reversible contraceptive (LARC)

Contraceptive methods that require administration less than once per menstrual cycle or month [8].

Contraceptive failure

A contraceptive failure is defined as a conception that occurred during a month in which a woman (or her partner) was using a contraceptive method, as long as she did not report that she (or he) had stopped use before having become pregnant [9].

Contraceptive continuation rate

The cumulative probability that acceptors of a contraceptive method will still be using any contraceptive method after a specified period of time (e.g., 1 year) [10].

Contraceptive discontinuation

Starting contraceptive use and then stopping before the specified period for any reason while still at risk of an unintended pregnancy.

Pearl index

Number of pregnancies per 100 woman-years (WY) of contraceptive use [11].

Randomized control trial

The randomised control trial (RCT) is a research study design in which subjects are randomly assigned to one of two groups: one (the experimental group) receiving the intervention that is being tested, and the other (the comparison group or control) receiving an alternative (conventional) treatment. The two groups are then followed up to see if there are any differences between them in outcome [12].

Unintended pregnancy

Unintended pregnancies are pregnancies that are reported to have been either unwanted i.e., they occurred when no children, or no more children, were desired or mistimed i.e., they occurred earlier than desired [13].

Exclusion criteria

We excluded studies that focussed on acceptability/feasibility /factors affecting use/utilization alone and abstracts in other languages. We excluded studies that had a different type of subdermal contraceptive implant as comparator, as this was not the purview of the health technology assessment under which this systematic review was conducted. Studies that focussed on specific timing of insertion of implant (like post-abortion or post-partum) and specific sub-groups like obese, human immunodeficiency virus (HIV) positive women etc. were excluded. The studies that looked at sub-group populations specifically were excluded because this review was meant to be applicable to the general population of reproductive age women.

Search strategy

A list of Medical subject headings (MeSH) and free text search words was made by conducting a preliminary search of relevant studies. The electronic databases that were searched were MEDLINE via PubMed, Cochrane library and Web of Science. Four clinical trial registries (Clinical trial registry of National institutes of Health [14], Clinical trials registry of India [15], EU clinical trials registry [16], The Australian New Zealand Clinical Trials Registry (ANZCTR [17]) were searched for relevant clinical trials. Grey literature search included unpublished conference abstracts, unpublished dissertations/thesis, government reports, government documents and product-related documents on ProQuest and Open Grey online platforms. The search strategy was developed using appropriate Boolean terms and the MEDLINE via PubMed strategy is enclosed in Additional file 1. The search strategy was adapted as per the specific norms of each separate electronic database. The reference list of all selected studies for critical appraisal was hand-searched for other relevant studies for the systematic review. The search was conducted by two researchers independently. All abstracts were reviewed and those fitting into the inclusion criteria were selected after excluding duplicates. Any disagreement between the two researchers was settled by a third researcher with mutual consensus.

Data collection and quality assessment strategy

The search was documented as per PRISMA guidelines [18]. A structured data extraction tool was used to extract the data. Methods, participant characteristics, interventions, comparators and outcomes were documented. Studies to be included for data extraction were assessed for quality. The quality of included studies in terms of methodology was critically assessed by two independent reviewers. Cochrane risk of bias tool [19] was used for randomized control trials; the risk of bias in non-randomized studies—of interventions (ROBINS-I) assessment tool was used to appraise non-randomized trials [20]; CASP checklist was used for cohort studies [21] and AXIS tool was used for cross-sectional studies [22]. The CASP checklist had 11 items on it. The tool does not have a scoring system; we hence used the following scoring to appraise the cohort studies: ≤ 2 negative attributes (no/can’t say) signified good quality; 3–5 negative attributes signified fair quality and ≥ 6 were marked as poor quality. The AXIS tool for cross sectional studies did not have a scoring system either, we used the following scoring method: of the 20 items on the tool; if ≤ 3 had negative attributes, it was marked as good quality; 4–8 was marked as fair quality and ≥ 9 was marked as poor quality.

Data analysis

A qualitative synthesis of included studies was done and is presented as text and summarized using tables. The narrative results compare and evaluate the study designs used and the key results among included studies. Analysis of heterogeneity was done based on study designs, comparators and outcomes reported among the included studies. The studies reporting clinical effectiveness and adverse effects were not eligible for meta-analysis due to different or no comparators. Clinical effectiveness was reported as pearl index i.e. pregnancies per woman-years of use, where data was available. Side-effects were reported as percentages. Meta-analyses were conducted using RevMan software to compare the one-year continuation rates of ESI with LNG-IUS and Copper-IUD. The summary measure in the meta-analysis was odds ratio. Percentages of continuation rates in ESI and LNG-IUS were extracted from included studies, entered in RevMan software to derive the pooled odds ratio. The forest plot and I2, to denote dispersion of effect sizes of included studies, generated from the software were reported. Reporting bias for these comparisons was assessed by constructing funnel plots.


The summary of the search is presented as a PRISMA flow chart in Fig. 1. The search yielded a total of 23,545 titles from the three electronic databases and grey literature. Among these, 467 titles were duplicates and subsequently 23,078 abstracts were screened. 164 full text articles were retrieved as they seemed to fit the inclusion criteria. Of these, 113 were excluded. Three of the studies had abstracts in English language but had full text in a language other than English; hence they were excluded. 29 studies were excluded because they focussed on specific timing of insertion of implant, for instance among women immediately post-abortion and post-partum. Studies that did not mention type of implant/ studied a different type of implant were excluded. Studies that focussed on specific sub-groups of population like prisoners, obese/overweight women, women with heart disease or epilepsy etc. were excluded. Six studies were excluded as the electronic database stated them as ‘inappropriate data collection’ in a narrative review on implanon [23].

Fig. 1
figure 1

Source: Constructed by authors

Flow chart of systematic review search and study selection. The flow chart is as per PRISMA guidelines for systematic reviews and shows the number of studies at each step of the review.

ProQuest and Open Grey forums were searched for unpublished articles. Key words from the search strategy were used in these websites. 28 working papers and conference titles were retrieved in ProQuest and 24 titles were available on Open Grey. None of the titles retrieved on ProQuest fit the inclusion criteria and were hence excluded. The titles on Open Grey were all in French and were hence excluded. A government of India report on an unpublished study on implanon was accessible to us. It was an executive summary of a Phase-III Multi-center clinical trial on ESI from India. 3119 women followed up for 93,617 women months showed that effectiveness was 100% and the overall continuation rate was 66.1 per 100 users at the end of 3 years. Frequent prolonged bleeding in women decreased over the three year duration of use from 11.8% at 3 months to 6.4% women at 36 months and amenorrhea increased from 11.6% at 3 months to 24.9% at 36 months [24].However all relevant data was not available to include the study in this review. Finally, 51 articles were included that addressed one or more of the outcomes; of which sixteen reported effectiveness of ESI. Side-effects of ESI were reported by 21 (41.2%) studies and 38 (74.5%) studies reported the continuation of implant by users in different parts of the world. The summary of findings of the 51 studies is presented in Table 1. Sixteen (31.4%) of the 51 studies reported more than one of the aforementioned outcomes. Most studies (28, 53.8%) compared ESI to other contraceptive methods. Five (9.8%) of the 51 studies were interventional trials, the rest were observational studies; five (9.8%) were cross-sectional and 30 (58.8%) were cohort studies (21 were prospective and 9 were retrospective). Eleven of the 51 (21.6%) studies were retrospective chart reviews. Of the 51 studies, five were drawn from the secondary analysis of the contraceptive CHOICE study. This was a prospective cohort study that promoted the use of long acting reversible methods in a region in the United States of America. Of the 51 studies, majority 34 (66.7%) were from high-income countries; 13 (25.5%) were from middle-income countries and 3(5.9%) in low income countries. One of the studies was a multi-country study.

Table 1 Table describing salient features of included studies

Effectiveness of ESI in comparison with other methods

Of the 15 studies that reported effectiveness of ESI, five of them reported pearl index and the values ranged between 0 and 1.4 unintended pregnancies per 100 woman-years. A multicenter trial from Mexico [25] reported a pearl index of zero with a follow up period of 958.5 woman years. Eight other studies that had no comparator(s) reported effectiveness of 98.5%, 99.2% and the rest 100% respectively [26,27,28,29,30,31,32,33]. Winner et al. compared the effectiveness of long acting reversible contraceptives (LARC: Copper IUD and ESI combined) to that of combined group Oral contraceptive pills, patch, vaginal ring and to Depot Medroxy Progesterone acetate (DMPA) in U.S.A and found that the LARC group had a failure rate of 0.3 per 100 woman years. The group of oral contraceptive pills, patch and vaginal ring had a pooled failure rate of 4.6 per 100 woman years and DMPA had a failure rate of 0.2 per 100 woman years [34]. The Winner et al. study did not report individual method wise effectiveness and instead reported grouped results for LARC and pills, patch and ring. A multicenter randomized control trial in Sweden reported a pearl index of 0.0 (95% CI 0–1.2) in ESI as compared to 0.9 (95% CI 0.2–2.6) in LNG-IUS [35]. Another study, a randomized patient preference trial in U.S.A that recruited 916 women, reported that as compared to grouped short acting reversible contraceptive SARC (pills and DMPA); grouped LARC (Copper IUD and ESI) had a significantly lower probability of unintended pregnancy (6.7 (3.6–12.1) in SARC versus 0.7 (0.0–4.7) in LARC) [36]. A multi-country RCT compared ESI and LNG-implants to Copper-IUD. They found ESI to have a lower failure rate: 0.4 per 100 woman years 95% confidence interval (CI 0.1–1.4) as compared to 2.8 (CI 1.3–6.0) in Copper IUD [37]. A study that analyzed insurance claims among 87,294 women in the USA reported an effectiveness of 98.8% of ESI as compared to 98.9% of LNG-IUS [38]. Secondary analysis of data from the contraceptive CHOICE project, done in U.S.A, reported combined LARC (LNG-IUS, Copper-IUD and implant) failure rate at 1, 2 and 3 years as 0.3%, 0.6% and 0.9% respectively; as compared to 4.8%, 7.8% and 9.4% among users of oral contraceptive pill, patch and vaginal ring. The study did not report method-wise failure rates [39]. Heterogeneity was present among studies that reported effectiveness in terms of study design and comparators and hence meta-analysis could not be conducted.

Side-effects of ESI as compared to other methods

41.2% (n = 21) of the 51 included studies reported side-effects of ESI. Of the 21 studies, 10 reported menstrual abnormalities; four were on metabolic effects, two on cancers, two on weight gain and body fat, and one each on depression, myocardial infarction/stroke and ovarian cysts.

Menstrual side-effects

A prospective study in Turkey with 80 participants reported amenorrhoea, infrequent menstrual bleeding and frequent menstrual bleeding among 33(41.3%), 19 (23.8%) and 14 women (17.5%), respectively [29]. Another prospective study from Nigeria with 32 women reported oligomenorrhea in 18 (56.3%); menorrhagia in 1(3.1%) and a combination in 13 (40.6%) women [27]. A retrospective clinic based study with 166 participants reported 40.4% with regular menstrual cycle and 30.3% having regular periods for a few months followed by amenorrhea. Prolonged menstrual bleeding was the most common side-effect reported [33]. A cross-sectional study of 860 women in Papua New Guinea had irregular bleeding as the most commonly reported side effect (20.6%) but only 7% said the bleeding was bothersome [30]. In the 90-day reference period of a pilot study from Turkey with 41 women, three of them (7.3%) had regular menstrual cycles, 14 (34.1%) had amenorrhoea and the remaining 24 (58.5%) had at least one type of abnormality in menstrual bleeding [40]. A multicentre retrospective study in Switzerland among 991 women over a median period of 7.4 months; reported infrequent bleeding (28%), amenorrhea (33%), prolonged bleeding (15%), and menometroorrhagia (16%) [41]. In a retrospective review of clinical records from U.S.A with 151 women, 25.2% contacted a health-care provider for abnormal bleeding [42]. A multi-country RCT showed that women with ESI had amenorrhea (38.9%), irregular bleeding (86.0%), heavy bleeding (35.4%) and prolonged bleeding (56.18%) as compared to women with Copper IUD who had a higher frequency of heavy bleeding(49.9%) and much lower frequency of amenorrhea (8.7%), irregular bleeding ( 38.9%) and prolonged bleeding (43.0%) [37].

Menstrual abnormalities have been recorded using different terminologies (infrequent bleeding, amenorrhea, prolonged bleeding, metromenorrhagia, frequent bleeding, oligomenorrhea, menorrhagia and bothersome bleeding) in different studies. Some of these terminologies do overlap. The terms which meant the same were combined and an average was calculated for the group for ESI. ‘Menorrhagia’, ‘increased bleeding’ and ‘heavy bleeding’ were combined and were found to be prevalent among 32.4% of the women. ‘Oligomenorrhea’, ‘irregular bleeding’ and ‘infrequent bleeding’ were combined and found to be 3.0%. ‘Amenorrhea’ and ‘absent bleeding’ were combined and found to be 15.4%. ‘Metrorrhagia’, ‘prolonged bleeding’, ‘dysfunctional uterine bleeding’ and ‘frequent bleeding’ were combined and found to be 23.3%.

Other short-term side-effects

Headache among users of ESI was reported in four (19.1%) of the 21 studies and frequency ranged from 5% to 59.6% [27, 35, 37, 41]. Reduction in libido was reported in one study at 9.4% [27]. Abdominal pain was reported among ESI users in a multicentre RCT up to 50.4% [37]. Acne was reported in four studies ranging from 11% to 45% [27, 35, 37, 40]. Other reported short-term side-effects were mastalgia, breast tenderness, emotional lability, mood changes and dizziness.

Metabolic side-effects

Two studies assessed weight gain among ESI users. A study done in U.S.A in 2019 showed no statistical difference in weight gain among users of ESI and non-users [43]. Another study, a prospective cohort study in Brazil of 150 women compared weight gain, body fat percentage and bone mineral density (BMD) among Copper-IUD and ESI users; findings showed that ESI users did not significantly differ in BMD at 12 months of use as compared to non-users. ESI users experienced gain in body weight of 4.1 kg at 12 months (p value: 0.001) as compared to a decrease in 0.1 kg body weight among Cu-IUD users. ESI users also showed a 2% higher gain in the percentage of body fat as compared to Copper-IUD users. Also, lean mass in ESI users significantly increased at 12 months (p = 0.020) [44]. A sub-study of the Contraceptive CHOICE Project considered 427 women for analysis and showed that there was no difference in weight gain among users of ESI, LNG-IUS or DMPA. Of the 427 users, 30.4% were ESI users who gained on an average 2.1 kg (SD = 6.7), 30.4% were LNG-IUS users who gained 1.0 kg (SD = 5.3), 15.7% were DMPA users who gained 2.2 kg (SD = 4.9) and 23.4% were Copper-IUD users who gained 0.2 kg (SD = 5.1) at the end of one year. However, people with darker skin colour were associated with significant weight gain (1.3 kg, 95% confidence interval = 0.2–2.4) as compared to other racial groups [45]. Parity, age, baseline weight and education of women were some of the covariates analysed by the CHOICE sub-study for continuation rate as an outcomes. No significant difference was found between ESI users and LNG-IUS users for these covariates. Two prospective studies from Brazil showed no significant decrease in total cholesterol, triglycerides and LDL, but a significant increase in mean haemoglobin, haematocrit and indirect bilirubin concentrations and of the HDL-C/TC and HDL-C/LDL-C ratios [46, 47]. A non-randomized open label trial from Brazil with 40 participants showed that ESI users did not have abnormalities in carbohydrate metabolism at 6, 12 months, as compared to baseline [48].

Long-term side effects

Three of the 51 studies reported long term effects of using ESI. A prospective cohort study of 1.8 million women in Denmark looked at incidence of ovarian and breast cancer among hormonal contraceptive users. The findings showed that users of progestogen-only products (including ESI) were not associated with ovarian cancer risk and that as compared with never users of contraception, relative risk of breast cancer among ESI users was 0.9 (0.5–1.8) [49, 50].The same Danish cohort also looked at incidence of myocardial infarction and stroke among hormonal contraceptive users and found that none of the progestin-only products, including the ESI, significantly increased the risk of thrombotic stroke or myocardial infarction [51]. A prospective study from Brazil with 344 women that looked at occurrence of ovarian cysts among ESI users concluded that the occurrence of ovarian cysts or persistent ovarian follicles in users of ESI was a common finding (26.7%) as compared to users of Copper-IUD (1.2%). The cysts became more frequent with time of use; however they regressed spontaneously within a short period of time and required no further treatment [52].

Continuation rate of ESI as compared to other methods

19 of the 38 studies that reported continuation rates did not have a comparator. Six of the studies compared ESI with short acting contraceptive methods like oral contraceptive pills, patch or vaginal ring along with at least one long acting method; 12 studies had only long acting contraceptives as comparators like LNG-IUS and Copper-IUD. Our meta-analysis showed that pooled one-year continuation rate was 84.8% for LNG-IUS and 83.0% for Copper-IUD as compared to 77.5% and 76.5% for ESI respectively. Twenty two of the 38 studies reported only continuation rates and not effectiveness/side-effects [42, 53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73]. In the studies, continuation rates varied from 57 to 97% at the end of first year of use, 44–95% at the end of second year and 25–78% by three years of use. A study done in 2010 used the term ‘removal rate’ of ESI. The study reported 25.2% removal rate with a median removal time of 9.8 months [74]. For studies that compared continuation rates of ESI and LNG-IUS and Copper-IUD, meta-analyses were conducted and forest plots were constructed in RevMan software. The meta-analyses presented in Fig. 2 show that odds ratio of one-year continuation rate is 1.6 (1.4, 1.8) for LNG-IUS vs. ESI and 1.3 (1.1, 1.6) for Copper-IUD vs. ESI, thus showing that continuation rates at the end of one-year were higher for LNG-IUS and Copper IUD as compared to ESI. The I2 statistic, that measures the variation across studies due to heterogeneity [75], for the two meta-analyses conducted were 90% and 88% respectively, showing that there was high dispersion of effect sizes in the included studies (as the I2 was > 75%). Even though the studies were homogenous in their designs and comparators; statistically there was high heterogeneity in the effect sizes. Meta-analysis could not be done for ESI versus DMPA as there was only one study that reported this comparison.

Fig. 2
figure 2

Source: Generated by authors using RevMan software

Meta-analyses of one-year continuation rates comparing ESI with LNG-IUS and copper-IUD. a, b Show the effect size for one year continuation rates for ESI compared to LNG-IUS and Copper-IUD respectively. The square boxes represent effect size of individual studies. The area of the square represents the weight of the study. The horizontal lines represent the limits of 95% confidence interval of the effect sizes. The vertical line is at 1, where there is no difference in continuation rates in the two methods. The diamond shape at the bottom of the plots represents the pooled odds ratio. In both cases it shows that continuation rates are lower in ESI.

Reporting bias was assessed for the studies reporting continuation rates and the funnel plots are presented in Fig. 3. The X-axis plots the odds ratios and the Y-axis plots the standard error. Each hollow circle represents one study. The asymmetry in Fig. 3a, b show that there was publication bias.

Fig. 3
figure 3

Source: Generated by authors using RevMan software

Funnel plots of studies reporting continuation rates comparing ESI with LNG-IUS and Copper-IUD. a, b Represents the distribution of effect sizes of included studies as a function of standard error comparing ESI with LNG-IUS and Copper-IUD respectively. The asymmetry in a and b show that there was publication bias. The X-axis plots the odds ratios and the Y-axis plots the standard error. Each hollow circle represents one study.

Risk of bias and critical appraisal of included studies

The risks of bias of the two included RCTs are presented in Table 2. Both RCTs have high risk of bias due to their open-label nature. One of them had high risk of bias in outcome assessment contributing to detection bias. Both RCTs had incomplete outcome data with attrition bias. The risk of bias in the three non-randomized trials (NRT) is presented in table number 2. Of the three NRTs; two had no clear information on addressing bias due to confounding factors and participant selection. One of the three NRTs has moderate risk of bias and two of them have serious risk of bias, based on the ROBIN-I tool. Based on the CASP tool, 26 (61.9%) of the cohort studies were ‘fair’ in quality; 5 (11.9%) were ‘poor’ and 11 (26.2%) were ‘good’. Of the 42 cohort studies, the common aspects contributing to poor/fair quality were incomplete follow-up, follow-up period being shorter than the three years (ESI use) and no mention of how confounding factors were addressed. Of the four cross sectional studies; all four were of ‘fair’ quality based on AXIS tool. The details of the critical appraisal of the 42 cohort studies and four cross-sectional studies are presented in the Additional file 2.

Table 2 Risk of bias in randomized and non-randomized trials


This systematic review was done in the context of a health technology assessment for etonogestrel subdermal implant (ESI). The protocol for the systematic review was registered in Prospero. We found that ESI was highly effective with pearl index < 1. The short term side-effects included menstrual disturbances (mainly amenorrhea and prolonged bleeding), headache, dizziness, weight gain and acne and were reported by 12 studies of the 51. There were no significant metabolic effects as reported by four studies and no increased risk of long-term adverse-effects like breast cancer, ovarian cancer, myocardial infarction or stroke as reported by two studies. There was an increased incidence of ovarian cysts that was reported by one study but none of the patients required treatment and the cysts regressed on their own after ESI was removed. One study reported that ESI users had a higher potential to develop depression [76]. In comparison to the other LARCs, effectiveness of ESI was the highest. Side-effect profile showed amenorrhea was highest in ESI. Despite the above mentioned advantages, the meta-analyses showed that ESI had lower one-year continuation rates as compared to LNG-IUS and Copper-IUD.

A Cochrane systematic review done in 2007 compared the effectiveness of ESI with other LARC including implants. This review included nine trials, of which eight compared ESI with Norplant (a Levonorgestrel-six-capsule implant) and one compared Jadelle (a Levonorgestrel-1-capsule-implant) with Norplant. The review showed that ESI was highly effective, with no pregnancies reported [77]. A Cochrane systematic review on effect of steroidal contraceptives on BMD included two studies on ESI; one of which fits the inclusion criteria of our review. The review, published in 2014 concluded that fracture risk due to steroidal contraceptives could not be determined from the then existing information [78]. Another Cochrane review that looked at use of progestin-only contraceptives (POC) and weight gain concluded in 2016 that the quality of the available evidence was low and that the 22 included studies showed inconclusive evidence of change in weight or body composition with use of POCs [79].

A systematic review done in 2017 on LARC pooled one-year continuation rates and found that Intrauterine device continuation was 74.0% (95% confidence interval 61.0–87.0%) and implant continuation was 84% (95% confidence interval 77.0–91.0%). This study states as a limitation the heterogeneity among the studies due to which not all continuation outcomes could be combined [80]. This study shows that ESI users have a higher one-year continuation rate as compared to IUD users. This is mainly because the review included women less than 25 years only (it focused on adolescent LARC use). Also, the study includes five studies, till 2016. In comparison, our review includes women of age group 15–49 years and includes studies till the year 2019.

The systematic review shows that ESI is highly effective, yet rate of discontinuation is higher as compared to LNG-IUS and Copper-IID according to our meta-analysis. This is attributed to the side effects of ESI. Of the 38 studies included in our review that report continuation rates; 27 reported reasons for discontinuation of ESI. The most common reasons for discontinuation were menstrual disturbances (6.25–62%) followed by weight gain, mood changes, headache and acne.

There is a huge difference in country representation of studies. As of May 2020, Nexplanon is available for use in 100 countries [81]. Yet, of the 51 included studies; 85% of the studies are from USA, Europe, Australia, Brazil or Mexico (High or upper-middle income countries). Only 7 studies are from low-middle and low income countries, all from Africa. Only one study is from an upper-middle income Asian country: Thailand. Effectiveness of ESI did not vary by country; however, continuation rates at one year were higher in low and low-middle income countries (≥ 85%) as compared to high income countries.

To the best of our knowledge, this is the first systematic review that compares ESI and other long acting reversible contraceptive methods with effectiveness, continuation rates and effects as outcomes. Though our systematic review was able to compare the one-year continuation rates of ESI with LNG-IUS and Copper-IUD by conducting meta-analyses; we were not able to make comparisons in effectiveness and side-effects due to heterogeneity in the studies.

The meta-analyses showed significantly lower one-year continuation rates for ESI as compared to LNG-IUS and Copper-IUD. The reasons for the same have been reported in multiple quantitative studies in literature. A few recent studies indicate reasons for high discontinuation rates among ESI users. A study done in Africa in 2020 reports high likelihood of discontinuation among women living in military camps, having less than three children, no history of previous contraceptive use, having experienced heavy or prolonged bleeding and those who were given poor information about the method [82]. Another study done in Africa in 2017 used mixed methods to determine reasons for discontinuation of implanon. The women who experienced side effects were more likely to discontinue it (Hazard ratio HR 3.6, 95% CI 1.60–8.11). The qualitative part of the study showed that unjustified advice for Implanon removal by non-gynaecologists, due to unrelated users' complaints, and deficient pre-insertion counselling were other causes of early removal.

In our study, of the 21 studies that reported side-effects; 10 reported reasons for discontinuation. Eight studies reported that either prolonged/irregular/increased bleeding were the commonest reasons for discontinuation. Thamkhantho et al. [33] reported that the reason for discontinuation was pain at insertion site (one out of 166). Aisien et al. [27] reported that two out of 32 discontinued one due to menorrhagia and the other due to headache. We have not included the reasons for discontinuation in our review, as that was not our objective; however, we make a call for research to compile evidence on reasons for differences in continuation rates among these long acting contraceptive methods.

Our review included all types of observational studies, including cross-sectional and case-note based studies, which are lower on the evidence pyramid as compared to RCTs. Hence, we calculated sensitivity and precision of our search with and without cross-sectional studies. We found that sensitivity remained unchanged but precision increased when cross-sectional studies were excluded [83].

The quality of included studies is also important in concluding this systematic review. Of the two RCTs, both were open label; attributing to high risk of performance bias. Overall, of the 51 included studies; 78.4% are either fair or poor in quality. The quality of available evidence has to be kept in mind while making policy-level or clinical recommendations about ESI. This will also play an important role in cost-effectiveness analysis involving etonogestrel contraceptive implant.


We conclude that ESI is safe and effective contraceptive method to use among women of reproductive age (15–49 years). Effectiveness and side-effect rates of ESI could not be pooled in contrast with other LARC due to study heterogeneity. Meta-analyses showed that one-year continuation rates in LNG-IUS were 1.55 (1.36, 1.76) times higher than in ESI users and that in Copper-IUD were 1.34 (1.13, 1.58) times higher than in ESI users. The overall evidence was moderate to low in quality.

Availability of data and materials

All included studies and their critical appraisal details are available in Additional file 2.



Copper intrauterine device


Depot medroxy progesterone acetate


Etonogestrel subdermal implant


Human immunodeficiency virus


Hazard ratio


Health technology assessment


Long acting reversible contraceptives


Levonorgestrel intrauterine system


Luteinizing hormone


Randomized control trial


Short acting reversible contraceptive


United Kingdom National Institute for Health and Care excellence


Unintended pregnancy


World Health Organization


  1. Bearak J, Popinchalk A, Alkema L, Sedgh G. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 2018;6(4):e380–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ganatra B, Gerdts C, Rossier C, Johnson BR, Tunçalp Ö, Assifi A, et al. Global, regional, and subregional classification of abortions by safety, 2010–14: estimates from a Bayesian hierarchical model. Lancet. 2017;390(10110):2372–81.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jain R, Muralidhar S. Contraceptive methods: needs, options and utilization. J Obstet Gynaecol India. 2011;61(6):626–34.

    Article  PubMed  Google Scholar 

  4. IMPLANON™ Package Insert [Internet]. FDA.

  5. Maddox DD, Rahman Z. Etonogestrel (Implanon), another treatment option for contraception. Pharm Ther. 2008;33(6):337–47.

    Google Scholar 

  6. Addendum to Clinical Guideline 30, Long-acting reversible contraception. This replaces Chapter 7: Progestogen-only subdermal implants (POSDIs) in clinical guideline 30—Google Search [Internet]. [cited 2018 Nov 6].

  7. Medical Eligibility Criteria for Implants | Family Planning [Internet]. [cited 2020 Nov 8].

  8. National Collaborating Centre for Women’s and Children’s Health (UK). Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-Acting Reversible Contraception [Internet]. London: RCOG Press; 2005 [cited 2018 Nov 6]. (National Institute for Health and Clinical Excellence: Guidance).

  9. Contraceptive Failure Rates: new estimates from the 1995 National Survey of Family Growth [Internet]. Guttmacher Institute. 2005 [cited 2018 Nov 8].

  10. Contraceptive Continuation rates—MEASURE Evaluation [Internet]. [cited 2020 Jun 27].

  11. Halpern V, Raymond EG, Lopez LM. Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy. Cochrane Database Syst Rev. 2010.

    Article  PubMed  Google Scholar 

  12. Kendall JM. Designing a research project: randomised controlled trials and their principles. Emerg Med J. 2003;20(2):164–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Brown S, Eisenberg L. The best intentions: unintended pregnancy and the well-being of children and families. Washington, DC: National Academy Press; 1995.

    Google Scholar 

  14. Background— [Internet]. [cited 2020 Feb 19].

  15. Clinical Trials Registry—India (CTRI) [Internet]. [cited 2020 Feb 19].

  16. Clinical Trials Register [Internet]. [cited 2020 Feb 19].

  17. ANZCTR [Internet]. [cited 2020 Feb 19].

  18. PRISMA [Internet]. [cited 2019 May 29].

  19. Cochrane Risk of Bias Tool [Internet]. [cited 2019 Jan 8].

  20. ROBINS-I tool [Internet]. [cited 2020 Jun 27].

  21. CASP-Cohort-Study-Checklist-2018_fillable_form.pdf [Internet]. [cited 2019 Jan 8].

  22. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS) | BMJ Open [Internet]. [cited 2020 Jun 27].

  23. Implanon: a review of the literature with recommendations for clinical management—PubMed [Internet]. [cited 2020 Jun 27].

  24. Phase-III Multicentre clinical trial with sub dermal single-rod contraceptive implant IMPLANON-R. An ICMR Task Force study.

  25. Flores JBO, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2005;90(3):228–33.

    Article  CAS  Google Scholar 

  26. Agrawal A, Robinson C. An assessment of the first 3 years’ use of Implanon in Luton. J Fam Plann Reprod Health Care. 2005;31(4):310–2.

    Article  PubMed  Google Scholar 

  27. Aisien AO, Enosolease ME. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract. 2010;13(3):331–5.

    CAS  PubMed  Google Scholar 

  28. Arribas-Mir L, Rueda-Lozano D, Agrela-Cardona M, Cedeño-Benavides T, Olvera-Porcel C, Bueno-Cavanillas A. Insertion and 3-year follow-up experience of 372 etonogestrel subdermal contraceptive implants by family physicians in Granada. Spain Contraception. 2009;80(5):457–62.

    Article  CAS  PubMed  Google Scholar 

  29. Gezginc K, Balci O, Karatayli R, Colakoglu MC. Contraceptive efficacy and side effects of Implanon. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2007;12(4):362–5.

    Article  CAS  Google Scholar 

  30. Gupta S, Mola G, Ramsay P, Jenkins G, Stein W, Bolnga J, et al. Twelve month follow-up of a contraceptive implant outreach service in rural Papua New Guinea. Aust N Z J Obstet Gynaecol. 2017;57(2):213–8.

    Article  PubMed  Google Scholar 

  31. Mutihir JT, Daru PH. Implanon sub-dermal implants: a 10-month review of acceptability in Jos, North-Central Nigeria. Niger J Clin Pract. 2008;11(4):320–3.

    CAS  PubMed  Google Scholar 

  32. Smith A, Reuter S. An assessment of the use of Implanon in three community services. J Fam Plann Reprod Health Care. 2002;28(4):193–6.

    Article  PubMed  Google Scholar 

  33. Thamkhantho M, Jivasak-Apimas S, Angsuwathana S, Chiravacharadej G, Intawong J. One-year assessment of women receiving sub-dermal contraceptive implant at Siriraj Family Planning Clinic. J Med Assoc Thail Chotmaihet Thangphaet. 2008;91(6):775–80.

    Google Scholar 

  34. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998–2007.

    Article  CAS  PubMed  Google Scholar 

  35. Apter D, Briggs P, Tuppurainen M, Grunert J, Lukkari-Lax E, Rybowski S, et al. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Fertil Steril. 2016;106(1):151-157.e5.

    Article  CAS  PubMed  Google Scholar 

  36. Hubacher D, Spector H, Monteith C, Chen P-L, Hart C. Long-acting reversible contraceptive acceptability and unintended pregnancy among women presenting for short-acting methods: a randomized patient preference trial. Am J Obstet Gynecol. 2017;216(2):101–9.

    Article  PubMed  Google Scholar 

  37. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod Oxf Engl. 2015;30(11):2527–38.

    Article  Google Scholar 

  38. Berenson AB, Tan A, Hirth JM. Complications and continuation rates associated with 2 types of long-acting contraception. Am J Obstet Gynecol. 2015;212(6):761.e1-8.

    Article  Google Scholar 

  39. Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Preventing unintended pregnancy: the contraceptive CHOICE Project in review. J Womens Health 2002. 2015;24(5):349–53.

    Google Scholar 

  40. Yildizbas B, Sahin HG, Kolusari A, Zeteroglu S, Kamaci M. Side effects and acceptability of Implanon: a pilot study conducted in eastern Turkey. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2007;12(3):248–52.

    Article  CAS  Google Scholar 

  41. Bitzer J, Tschudin S, Alder J, Swiss Implanon Study Group. Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2004;9(4):278–84.

  42. Casey SE, Cannon A, Mushagalusa Balikubirhi B, Muyisa J-B, Amsalu R, Tsolka M. Twelve-month contraceptive continuation among women initiating short- and long-acting reversible contraceptives in North Kivu, Democratic Republic of the Congo. PLoS ONE. 2017;12(9):e0182744.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Romano ME, Braun-Courville DK. Assessing weight status in adolescent and young adult users of the etonogestrel contraceptive implant. J Pediatr Adolesc Gynecol. 2019;32(4):409–14.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Modesto W, Dal Ava N, Monteiro I, Bahamondes L. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet. 2015;292(6):1387–91.

    Article  CAS  PubMed  Google Scholar 

  45. Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013;88(4):503–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Guazzelli CAF, de Queiroz FT, Barbieri M, Barreiros FA, Torloni MR, Araujo FF. Metabolic effects of contraceptive implants in adolescents. Contraception. 2011;84(4):409–12.

    Article  CAS  PubMed  Google Scholar 

  47. Villas-Boas J, Vilodre LC, Malerba H, Pontremoli Salcedo M, Foresti Jiménez M, El Beitune P. Metabolic safety of the etonogestrel contraceptive implant in healthy women over a 3-year period. Eur J Obstet Gynecol Reprod Biol. 2016;202:51–4.

    Article  CAS  PubMed  Google Scholar 

  48. Oderich CL, Wender MCO, Lubianca JN, Santos LM, de Mello GC. Impact of etonogestrel-releasing implant and copper intrauterine device on carbohydrate metabolism: a comparative study. Contraception. 2012;85(2):173–6.

    Article  CAS  PubMed  Google Scholar 

  49. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–39.

    Article  PubMed  Google Scholar 

  50. Iversen L, Fielding S, Lidegaard Ø, Mørch LS, Skovlund CW, Hannaford PC. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ. 2018;26:k3609.

    Article  Google Scholar 

  51. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366(24):2257–66.

    Article  CAS  PubMed  Google Scholar 

  52. Hidalgo MM, Lisondo C, Juliato CT, Espejo-Arce X, Monteiro I, Bahamondes L. Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants. Contraception. 2006;73(5):532–6.

    Article  CAS  PubMed  Google Scholar 

  53. Abraham M, Zhao Q, Peipert JF. Young age, nulliparity, and continuation of long-acting reversible contraceptive methods. Obstet Gynecol. 2015;126(4):823–9.

    Article  PubMed  Google Scholar 

  54. Agostini A, Godard C, Laurendeau C, Benmahmoud Zoubir A, Lafuma A, Lévy-Bachelot L, et al. Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2018;23(6):421–6.

    Article  CAS  Google Scholar 

  55. Berlan E, Mizraji K, Bonny AE. Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting. Contraception. 2016;94(1):81–6.

    Article  CAS  PubMed  Google Scholar 

  56. Cea Soriano L, Wallander M-A, Andersson S, Filonenko A, García Rodríguez LA. The continuation rates of long-acting reversible contraceptives in UK general practice using data from The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2015;24(1):52–8.

    Article  PubMed  Google Scholar 

  57. Chiles DP, Roberts TA, Klein DA. Initiation and continuation of long-acting reversible contraception in the United States military healthcare system. Am J Obstet Gynecol. 2016;215(3):328.e1-9.

    Article  Google Scholar 

  58. Griffiths EK, Marley JV, Friello D, Atkinson DN. Uptake of long-acting, reversible contraception in three remote Aboriginal communities: a population-based study. Med J Aust. 2016;205(1):21–5.

    Article  PubMed  Google Scholar 

  59. Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol. 2013;122(6):1214–21.

    Article  CAS  PubMed  Google Scholar 

  60. Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception. 2009;80(6):527–32.

    Article  PubMed  Google Scholar 

  61. Howard DL, Ford A, Ceballos S, Volker KW. Temporal trends in the uptake and continuation of the etonogestrel implant in a large private practice setting. J Womens Health 2002. 2018;27(2):191–5.

    Google Scholar 

  62. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 2006;74(4):287–9.

    Article  PubMed  Google Scholar 

  63. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105–13.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Peterson AM, Brown A, Savage A, Dempsey A. Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2019;24(6):475–9.

    Article  Google Scholar 

  65. Rominski SD, Manu A, Maya E, Morhe ESK, Dalton VK. Discontinuation of long-acting reversible contraception versus short-term hormonal methods in urban Ghana: a pilot longitudinal study. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2018;142(2):235–6.

    Article  Google Scholar 

  66. Sanders JN, Turok DK, Gawron LM, Law A, Wen L, Lynen R. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review. Am J Obstet Gynecol. 2017;216(6):590.e1-590.e8.

    Article  Google Scholar 

  67. Short M, Dallay D, Omokanye S, Hanisch JU, Inki P. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2012;17(1):79–88.

    Article  CAS  Google Scholar 

  68. Sznajder KK, Tomaszewski KS, Burke AE, Trent M. Incidence of discontinuation of long-acting reversible contraception among adolescent and young adult women served by an urban primary care clinic. J Pediatr Adolesc Gynecol. 2017;30(1):53–7.

    Article  PubMed  Google Scholar 

  69. Teunissen AM, Grimm B, Roumen FJME. Continuation rates of the subdermal contraceptive Implanon(®) and associated influencing factors. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2014;19(1):15–21.

    Article  CAS  Google Scholar 

  70. Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept. 2014;19(1):5–14.

    Article  CAS  Google Scholar 

  71. Early Implanon discontinuation rate and its associated factors in health institutions of Mekelle City, Tigray, Ethiopia 2016/17 [Internet]. [cited 2020 Feb 19].

  72. O’neil-Callahan M, Peipert JF, Zhao Q, Madden T, Secura G. Twenty-four-month continuation of reversible contraception. Obstet Gynecol. 2013;122(5):1083–91.

    Article  PubMed  CAS  Google Scholar 

  73. Discontinuation rate of Implanon and its associated factors among women who ever used Implanon in Dale District, Southern Ethiopia [Internet]. [cited 2020 Feb 19].

  74. Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception. 2011;83(5):426–30.

    Article  CAS  PubMed  Google Scholar 

  75. Heterogeneity in Meta-analysis (Q, I-square)—StatsDirect [Internet]. [cited 2020 Nov 8].

  76. Smith K, Nayyar S, Rana T, Archibong AE, Looney KR, Nayyar T. Do progestin-only contraceptives contribute to the risk of developing depression as implied by beta-arrestin 1 levels in leukocytes? A pilot study. Int J Environ Res Public Health [Internet]. 2018 Sep [cited 2020 May 21];15(9).

  77. Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Cochrane Database Syst Rev. 2007;(3):CD001326.

  78. Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev [Internet]. 2014 [cited 2020 Jun 5].

  79. Lopez LM, Bernholc A, Chen M, Grey TW, Otterness C, Westhoff C, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2016;(8):CD008452.

  80. Diedrich JT, Klein DA, Peipert JF. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(4):364.e1-364.e12.

    Article  Google Scholar 

  81. Paynter M. Nexplanon, a 3-year birth control implant, is now approved for use in Canada [Internet]. The Conversation. [cited 2020 Jul 20].

  82. Akilimali PZ, J H, P A, K P K, J B. . Incidence and determinants of Implanon discontinuation: findings from a prospective cohort study in three health zones in Kinshasa, DRC. PLoS One. 2020;15(5):e0232582.

  83. Chapter 4: Searching for and selecting studies [Internet]. [cited 2020 Dec 1].

Download references


We acknowledge the encouragement of the Director General, Indian Council of Medical Research and Secretary Department of Health Research, Government of India, and the Director of National Institute for Research in Reproductive Health, Mumbai for their encouragement and support. We acknowledge the capacity building and training we recieved from the Department of Health Research Secretariat, Ministry of health and Family Welfare, Government of India. 


There was no internal or institutional funding. The study is part of the Health Technology Assessment project for Nexplanon which was funded by Department of Health Research, MoHFW, India. One of the authors (OS) is engaged in the scientific work at the secretariat of the funding agency. The role of this author was in conceptualization, design and review of the study.

Author information

Authors and Affiliations



All authors contributed to conception and design of the study. KM, BJ and HC were involved in data collection and analysis. Critical appraisal of included studies was done by KM, BJ and OS. BJ and OS supervised the work. KM drafted the manuscript and all authors have reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Beena Joshi.

Ethics declarations

Ethics approval and consent to participate

Since this was part of a larger HTA study, ethical approval was sought for the entire HTA study.

Consent for publication

Not applicable. (As we did not collect individual patient data for this study).

Competing interests

The manufacturers of Nexplanon/Implanon-NXT are stakeholders in the HTA project undertaken by the technical partner of HTA-In. Technical inputs about the product were obtained from the manufacturers, they had no other influence (financial or otherwise) over the team that worked on the HTA/the decision makers. The team declares no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Search terms and search strategy. Two tables are included here. The first one lists the search terms and the second lists the search strategy.

Additional file 2:

Critical appraisal of included studies. Four tables that describe the critical appraisal of included studies.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moray, K.V., Chaurasia, H., Sachin, O. et al. A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant. Reprod Health 18, 4 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: